JP2021527062A5 - - Google Patents
Info
- Publication number
- JP2021527062A5 JP2021527062A5 JP2020567973A JP2020567973A JP2021527062A5 JP 2021527062 A5 JP2021527062 A5 JP 2021527062A5 JP 2020567973 A JP2020567973 A JP 2020567973A JP 2020567973 A JP2020567973 A JP 2020567973A JP 2021527062 A5 JP2021527062 A5 JP 2021527062A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- level
- complement factor
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024088364A JP2024114706A (ja) | 2018-06-07 | 2024-05-30 | ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682013P | 2018-06-07 | 2018-06-07 | |
| US62/682,013 | 2018-06-07 | ||
| PCT/US2019/035758 WO2019236820A1 (en) | 2018-06-07 | 2019-06-06 | Dosing and effect of c5a antagonist with anca-associated vasculitis |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024088364A Division JP2024114706A (ja) | 2018-06-07 | 2024-05-30 | ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021527062A JP2021527062A (ja) | 2021-10-11 |
| JP2021527062A5 true JP2021527062A5 (OSRAM) | 2022-06-13 |
Family
ID=68764799
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020567973A Pending JP2021527062A (ja) | 2018-06-07 | 2019-06-06 | ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果 |
| JP2024088364A Pending JP2024114706A (ja) | 2018-06-07 | 2024-05-30 | ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024088364A Pending JP2024114706A (ja) | 2018-06-07 | 2024-05-30 | ＡＮＣＡ関連血管炎に対するｃ５ａアンタゴニストの投薬及び効果 |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US11191756B2 (OSRAM) |
| EP (1) | EP3801519A4 (OSRAM) |
| JP (2) | JP2021527062A (OSRAM) |
| KR (2) | KR20210018906A (OSRAM) |
| CN (1) | CN112423752A (OSRAM) |
| AU (1) | AU2019282327B2 (OSRAM) |
| BR (1) | BR112020024842A2 (OSRAM) |
| CA (1) | CA3102403A1 (OSRAM) |
| CL (1) | CL2020003171A1 (OSRAM) |
| IL (1) | IL279188B2 (OSRAM) |
| MA (1) | MA52808A (OSRAM) |
| MX (1) | MX2020013166A (OSRAM) |
| SG (1) | SG11202011961YA (OSRAM) |
| WO (1) | WO2019236820A1 (OSRAM) |
| ZA (1) | ZA202007615B (OSRAM) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3102403A1 (en) | 2018-06-07 | 2019-12-12 | Chemocentryx, Inc. | Dosing and effect of c5a antagonist with anca-associated vasculitis |
| EP4487915A3 (en) | 2018-11-30 | 2025-03-19 | ChemoCentryx, Inc. | Capsule formulations |
| MX2022005406A (es) | 2019-11-08 | 2022-05-24 | Chemocentryx Inc | Forma amorfa de un receptor de componente c5a de complemento. |
| CN118908883A (zh) * | 2019-11-08 | 2024-11-08 | 凯莫森特里克斯股份有限公司 | 补体成分c5a受体的盐形式 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1739078A1 (de) | 2005-05-30 | 2007-01-03 | Jerini AG | C5a-Rezeptor-Antagonisten |
| WO2008079371A1 (en) * | 2006-12-22 | 2008-07-03 | Encysive Pharmaceuticals, Inc. | Modulators of c3a receptor and methods of use thereof |
| CN104193824A (zh) * | 2008-02-20 | 2014-12-10 | G2炎症私人有限公司 | 人源化抗-C5aR抗体 |
| US20110275639A1 (en) * | 2008-12-22 | 2011-11-10 | Chemocentryx, Inc. | C5aR ANTAGONISTS |
| SMT202200074T1 (it) | 2008-12-22 | 2022-03-21 | Chemocentryx Inc | Antagonisti di c5ar |
| HRP20171176T1 (hr) | 2010-06-24 | 2017-10-06 | Chemocentryx, Inc. | C5ar antagonisti |
| EP3682879B1 (en) | 2014-09-29 | 2022-08-03 | ChemoCentryx, Inc. | Processes and intermediates in the preparation of c5ar antagonists |
| EP3283889B1 (en) | 2015-04-17 | 2020-02-26 | Euroimmun Medizinische Labordiagnostika AG | Method and assay for diagnosing rapidly progressive glomerulonephritis in a subject |
| WO2017176620A2 (en) | 2016-04-04 | 2017-10-12 | Chemocentryx, Inc. | SOLUBLE C5aR ANTAGONISTS |
| US20190134020A1 (en) * | 2017-10-31 | 2019-05-09 | Chemocentryx, Inc. | C5aR INHIBITOR REDUCTION OF URINARY sCD163 |
| CA3102403A1 (en) | 2018-06-07 | 2019-12-12 | Chemocentryx, Inc. | Dosing and effect of c5a antagonist with anca-associated vasculitis |
-
2019
- 2019-06-06 CA CA3102403A patent/CA3102403A1/en active Pending
- 2019-06-06 SG SG11202011961YA patent/SG11202011961YA/en unknown
- 2019-06-06 KR KR1020217000253A patent/KR20210018906A/ko not_active Ceased
- 2019-06-06 BR BR112020024842-8A patent/BR112020024842A2/pt unknown
- 2019-06-06 AU AU2019282327A patent/AU2019282327B2/en active Active
- 2019-06-06 EP EP19814841.3A patent/EP3801519A4/en active Pending
- 2019-06-06 CN CN201980038855.4A patent/CN112423752A/zh active Pending
- 2019-06-06 JP JP2020567973A patent/JP2021527062A/ja active Pending
- 2019-06-06 MA MA052808A patent/MA52808A/fr unknown
- 2019-06-06 KR KR1020267004102A patent/KR20260027358A/ko active Pending
- 2019-06-06 MX MX2020013166A patent/MX2020013166A/es unknown
- 2019-06-06 US US16/433,487 patent/US11191756B2/en active Active
- 2019-06-06 WO PCT/US2019/035758 patent/WO2019236820A1/en not_active Ceased
- 2019-06-06 IL IL279188A patent/IL279188B2/en unknown
-
2020
- 2020-12-04 CL CL2020003171A patent/CL2020003171A1/es unknown
- 2020-12-07 ZA ZA2020/07615A patent/ZA202007615B/en unknown
-
2021
- 2021-11-04 US US17/519,266 patent/US12350263B2/en active Active
-
2024
- 2024-05-30 JP JP2024088364A patent/JP2024114706A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020516646A5 (OSRAM) | ||
| JP2023078341A5 (OSRAM) | ||
| JP2020517696A5 (OSRAM) | ||
| JP2006514689A5 (ja) | １−オキソ−２−（２，６−ジオキソピペリジン−３−イル）−４−メチルイソインドリンを含む脳腫瘍の治療及び管理のための医薬組成物 | |
| IL320452A (en) | Combination therapy for prostate cancer | |
| JP2019529581A5 (OSRAM) | ||
| JP2013521303A5 (OSRAM) | ||
| JP2023076465A5 (OSRAM) | ||
| JP2022527398A5 (OSRAM) | ||
| JP2017525713A5 (OSRAM) | ||
| JP2022062170A5 (OSRAM) | ||
| RU2017116740A (ru) | Комбинации для лечения рассеянного склероза | |
| JP2023530264A5 (OSRAM) | ||
| JP2021534129A5 (OSRAM) | ||
| JP2018065829A5 (OSRAM) | ||
| JP2023549849A5 (OSRAM) | ||
| JP2019524820A5 (OSRAM) | ||
| JP2022546456A5 (OSRAM) | ||
| ZA202007615B (en) | Dosing and effect of c5a antagonist with anca-associated vasculitis | |
| JP2022517902A5 (OSRAM) | ||
| JP2025509278A5 (OSRAM) | ||
| JP2024512558A5 (OSRAM) | ||
| EP3592351A1 (en) | 1-piperidinepropionic acid for treating a fibrosing disease | |
| RU2020142621A (ru) | Дозирование и эффект c5a антагониста при anca-ассоциированном васкулите | |
| RU2019126627A (ru) | Схема введения доз комбинации церитиниба и молекулы антитела к pd-1 |